Skip to main content
logo
Fate Therapeutics, Inc. (FATE)
NASDAQ: FATE · Real-Time Price · USD
1.100
+0.020 (1.85%)
At close: Mar 20, 2026, 4:00 PM EDT
1.130
+0.030 (2.73%)
After-hours: Mar 20, 2026, 7:29 PM EDT

Fate Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
6.6513.6363.5396.355.85
Revenue Growth (YoY)
-51.24%-78.55%-34.03%72.44%77.66%
Gross Profit
6.6513.6363.5396.355.85
Selling, General & Admin
46.5274.1781.4584.2357.32
Research & Development
107.83135172.6320.45215.52
Other Operating Expenses
-14.74---
Total Operating Expenses
154.35223.91254.04404.69272.84
Operating Income
-147.7-210.28-190.51-308.39-216.99
Interest Income
11.0517.2917.195.841.31
Other Non-Operating Income (Expense)
0.346.7312.420.823.53
Total Non-Operating Income (Expense)
11.3924.0129.5826.674.84
Pretax Income
-136.32-186.26-160.93-281.72-212.15
Net Income
-136.32-186.26-160.93-281.72-212.15
Net Income to Common
-136.32-186.26-160.93-281.72-212.15
Shares Outstanding (Basic)
119114989795
Shares Outstanding (Diluted)
119114989795
Shares Change (YoY)
4.49%15.86%1.34%2.19%15.00%
EPS (Basic)
-1.15-1.64-1.64-2.91-2.24
EPS (Diluted)
-1.15-1.64-1.64-2.91-2.24
Free Cash Flow
-112.04-123.6-138.42-283.77-213.57
Free Cash Flow Per Share
-0.94-1.09--2.93-2.25
Gross Margin
100.00%100.00%100.00%100.00%100.00%
Operating Margin
-2222.45%-1542.63%-299.86%-320.23%-388.56%
Profit Margin
-2051.08%-1366.46%-253.30%-292.55%-379.89%
FCF Margin
-1685.78%-906.79%-217.86%-294.68%-382.43%
EBITDA
-134.8-191.31-172.23-294.63-211.14
EBITDA Margin
-2028.33%-1403.52%-271.09%-305.95%-378.08%
EBIT
-147.7-210.28-190.51-308.39-216.99
EBIT Margin
-2222.45%-1542.63%-299.86%-320.23%-388.56%
Updated Feb 26, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q